How To Establish Strategic Readiness For First-In-Human Trials

By Angela Thompson and Raul P. Lima, inSeption Group

FIH clinical trials are where promising programs either accelerate or begin to fall behind. Many teams assume IND clearance signals readiness, but delays often emerge from gaps between regulatory approval and clinical execution. When regulatory, clinical, and operational efforts are not aligned early, risks compound quickly and timelines begin to slip. The most successful programs treat readiness as a coordinated effort, not a milestone. They align cross-functional teams early to identify gaps, clarify priorities, and build a cohesive strategy before execution begins. Without that alignment, challenges related to protocol design, safety, vendor coordination, and data integration often surface too late to resolve efficiently.

As programs enter clinical execution, complexity increases, especially when multiple partners and systems are involved. Decisions around study design, site selection, and data collection carry downstream consequences that can either enable smooth execution or create costly friction.

Teams that integrate regulatory and clinical planning from the outset are better positioned to maintain momentum, avoid preventable delays, and execute with confidence.

Read the full article to understand where FIH readiness breaks down, how to identify hidden risks early, and what it takes to align regulatory and clinical execution before delays impact your timeline.